Evidence map›Paper›PMID 41407457›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025

[Clinical efficacy and safety of CLAE regimen for refractory/relapsed T cell acute lymphoblastic leukemia/lymphoma: a prospective, multicenter, single-arm study].

Y Li, X Zhang, X H Sun, J Song, R Zhang, P Yang, W Wan, F Dong, J J Wang, H M Jing

Abstract readMulticenter StudyEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Y LiPeking University Third Hospital, Beijing 100191, China.
X ZhangHebei Yanda Lu Daopei Hospital, Langfang 065206, China.
X H SunThe Second Hospital of Dalian Medical University, Dalian 116023, China.
J SongTianjin Medical University General Hospital, Tianjin 300052, China.
R ZhangShengjing Hospital of China Medical University, Shenyang 110004, China.
P YangPeking University Third Hospital, Beijing 100191, China.
W WanPeking University Third Hospital, Beijing 100191, China.
F DongPeking University Third Hospital, Beijing 100191, China.
J J WangPeking University Third Hospital, Beijing 100191, China.
H M JingPeking University Third Hospital, Beijing 100191, China.

Funding

Beijing Municipal Science&Technology Commission: Research, transformation and application of Capital's Clinical Diagnosis and Treatment Technologies Z211100002921036The special fund of the National Clinical Key Specialty Construction Program 2023Wu Jieping Medical Foundation: The Special Fund for Clinical Scientific Research 320.6750.2021-04-25
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultCytarabineEtoposideFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeYoung AdultCytarabineEtoposideCladribineCytarabineEtoposidePrecursor T-cell lymphoblastic leukemia-lymphomaRecurrenceRefractory Diseases

Identifiers

PMID41407457
PMCPMC12708957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.